Antimicrobial-Resistant Nontyphoidal Salmonella Infection Following International Travel-United States, 2018-2019

J Infect Dis. 2023 Aug 31;228(5):533-541. doi: 10.1093/infdis/jiad128.

Abstract

Background: Antimicrobial resistance in nontyphoidal Salmonella (NTS) can limit treatment options. We assessed the contribution of international travel to antimicrobial-resistant NTS infections.

Methods: We describe NTS infections that were reported to the Foodborne Diseases Active Surveillance Network during 2018-2019 and screened for genetic resistance determinants, including those conferring decreased susceptibility to first-line agents (ciprofloxacin, ceftriaxone, or azithromycin). We used multivariable logistic regression to assess the association between resistance and international travel during the 7 days before illness began. We estimated the contribution of international travel to resistance using population-attributable fractions, and we examined reported antimicrobial use.

Results: Among 9301 NTS infections, 1159 (12%) occurred after recent international travel. Predicted resistance to first-line antimicrobials was more likely following travel; the adjusted odds ratio varied by travel region and was highest after travel to Asia (adjusted odds ratio, 7.2 [95% confidence interval, 5.5-9.5]). Overall, 19% (95% confidence interval, 17%-22%) of predicted resistance to first-line antimicrobials was attributable to international travel. More travelers than nontravelers receiving ciprofloxacin or other fluoroquinolones had isolates with predicted resistance to fluoroquinolones (29% vs 9%, respectively; P < .01).

Conclusions: International travel is a substantial risk factor for antimicrobial-resistant NTS infections. Understanding risks of resistant infection could help target prevention efforts.

Keywords: drug resistance; foodborne disease; salmonella; travel.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Humans
  • Microbial Sensitivity Tests
  • Salmonella / genetics
  • Salmonella Infections* / drug therapy
  • Salmonella Infections* / epidemiology
  • United States / epidemiology

Substances

  • Ciprofloxacin
  • Anti-Infective Agents
  • Anti-Bacterial Agents